nach oben

Current Atherosclerosis Reports

Erschienen in:

01.06.2012 | Genetics (AJ Marian, Section Editor)

Sortilin as a Regulator of Lipoprotein Metabolism

verfasst von: Alanna Strong, Daniel J. Rader

Erschienen in: Current Atherosclerosis Reports | Ausgabe 3/2012

Einloggen, um Zugang zu erhalten

Abstract

Elevated low-density lipoprotein cholesterol (LDL-C) is associated with increased risk of atherosclerotic cardiovascular disease (ASCVD) and myocardial infarction (MI). Much of the insight into LDL metabolism has been gained through the study of Mendelian disorders of lipid metabolism. Genome-wide associations studies (GWAS) are now being used to identify novel genes and loci that contribute to variations in LDL-C levels, and they have identified the SORT1 gene as an important modulator of LDL-C levels and ASCVD risk. Mechanistic studies in mice and cell culture also suggest that the SORT1 gene is an important regulator of lipoprotein metabolism; however, these studies disagree on the directionality of the effect of Sort1 expression on plasma lipids and the mechanism for the lipid changes. Here we review the identification of the SORT1 locus as a modulator of LDL-C levels and ASCVD risk and the first mechanistic studies that explore the role of Sortilin in lipid metabolism.

Lloyd-Jones D, et al. Executive summary: heart disease and stroke statistics—2010 update: a report from the American Heart Association. Circulation. 2010;121:948–54.

Lusis AJ. Atherosclerosis. Nature. 2000;407:233–41.PubMedCrossRef

Waters DD, et al. Lipid treatment assessment project 2: a multinational survey to evaluate the proportion of patients achieving low-density lipoprotein cholesterol goals. Circulation. 2009;120:28–34.PubMedCrossRef

Hobbs HaD. In: Harrison’s principles of internal medicine. McGraw Hill; 2007. pp. 2416–29.

Kathiresan S, et al. Six new loci associated with blood low-density lipoprotein cholesterol, high-density lipoprotein cholesterol or triglycerides in humans. Nat Genet. 2008;40:189–97.PubMedCrossRef

Willer CJ, et al. Newly identified loci that influence lipid concentrations and risk of coronary artery disease. Nat Genet. 2008;40:161–9.PubMedCrossRef

• Kathiresan S, et al. Common variants at 30 loci contribute to polygenic dyslipidemia. Nat Genet. 2009;41:56–65. This is a genome-wide association study in European populations identifying 10 novel genetic determinants of lipid traits.PubMedCrossRef

• Teslovich TM, et al. Biological, clinical and population relevance of 95 loci for blood lipids. Nature. 2010;466;707–13. This is the largest genome-wide association study for lipid traits, and it identified 95 total loci associated with lipid traits, including 59 novel loci. Many of these loci were replicated in non-European populations as well. This study named the SORT1 locus as a genome-wide significant determinant of LDL-C levels and cardiovascular disease risk in European and non-European populations with the lowest P-value in the human genome for LDL-C.

Samani NJ, et al. Genomewide association analysis of coronary artery disease. N Engl J Med. 2007;357:443–53.PubMedCrossRef

10.

• Schunkert H, et al. Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease. Nat Genet. 2011;43:333–8. This large-scale genome-wide association study for cardiovascular disease with 135,000 individuals of European descent identified 13 novel loci for CAD.

11.

Qi L, et al. Genetic risk score and risk of myocardial infarction in Hispanics. Circulation. 2011;123;374–80.

12.

Zhou L, et al. Genetic variants at newly identified lipid loci are associated with coronary heart disease in a Chinese Han population. PLoS One. 2011;6:e27481.

13.

• Kathiresan S, et al. Genome-wide association of early-onset myocardial infarction with single nucleotide polymorphisms and copy number variants. Nat Genet. 2009;41:334–41. This is a genome-wide association study of cardiovascular disease and early-onset myocardial infarction.PubMedCrossRef

14.

Chasman DI, et al. Genetic loci associated with plasma concentration of low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, triglycerides, apolipoprotein A1, and Apolipoprotein B among 6382 white women in genome-wide analysis with replication. Circ Cardiovasc Genet. 2008;1:21–30.PubMedCrossRef

15.

• Linsel-Nitschke P, et al. Genetic variation at chromosome 1p13.3 affects sortilin mRNA expression, cellular LDL-uptake and serum LDL levels which translates to the risk of coronary artery disease. Atherosclerosis. 2010;208:183–9. This is the first mechanistic study associating elevated Sort1 expression with increased LDL uptake.

16.

Nakayama K, et al. Large scale replication analysis of loci associated with lipid concentrations in a Japanese population. J Med Genet. 2009;46:370–4.PubMedCrossRef

17.

• Musunuru K, et al. From noncoding variant to phenotype via SORT1 at the 1p13 cholesterol locus. Nature. 2010;466:714–9. This study identified the causal SNP at the 1p13 locus that confers the expression changes seen with the minor allele and in vivo proof of principles studies showing that Sort1 overexpression reduces plasma cholesterol and VLDL secretion, whereas Sort1 knockdown increases plasma cholesterol and VLDL secretion.

18.

Gupta R, et al. Association of common DNA sequence variants at 33 genetic loci with blood lipids in individuals of African ancestry from Jamaica. Hum Genet. 2010;128:557–61.

19.

Keebler ME, et al. Association of blood lipids with common DNA sequence variants at 19 genetic loci in the multiethnic United States National Health and Nutrition Examination Survey III. Circ Cardiovasc Genet. 2009;2:238–43.PubMedCrossRef

20.

Nielsen MS, et al. The sortilin cytoplasmic tail conveys Golgi-endosome transport and binds the VHS domain of the GGA2 sorting protein. EMBO J. 2001;20:2180–90.PubMedCrossRef

21.

Nykjaer A, et al. Sortilin is essential for proNGF-induced neuronal cell death. Nature. 2004;427:843–8.PubMedCrossRef

22.

• Hu F, et al. Sortilin-mediated endocytosis determines levels of the frontotemporal dementia protein, progranulin. Neuron. 2010;68:654–67. This study shows that SORT1 mediates the lysosomal degradation of progranulin and shows a functional relationship between sortilin and frontotemporal dementia.

23.

Navarro V, Vincent JP, Mazella J. Shedding of the luminal domain of the neurotensin receptor-3/sortilin in the HT29 cell line. Biochem Biophys Res Commun. 2002;298:760–4.PubMedCrossRef

24.

Evans SF, et al. Neuronal brain-derived neurotrophic factor is synthesized in excess, with levels regulated by sortilin-mediated trafficking and lysosomal degradation. J Biol Chem. 2011;286:29556–67.

25.

Nielsen MS, Jacobsen C, Olivecrona G, Gliemann J, Petersen CM. Sortilin/neurotensin receptor-3 binds and mediates degradation of lipoprotein lipase. J Biol Chem. 1999;274:8832–6.PubMedCrossRef

26.

Jacobsen L, et al. Activation and functional characterization of the mosaic receptor SorLA/LR11. J Biol Chem. 2001;276:22788–96.PubMedCrossRef

27.

Nilsson SK, et al. Endocytosis of apolipoprotein A-V by members of the low density lipoprotein receptor and the VPS10p domain receptor families. J Biol Chem. 2008;283:25920–7.PubMedCrossRef

28.

• Kjolby M, et al. Sort1, encoded by the cardiovascular risk locus 1p13.3, is a regulator of hepatic lipoprotein export. Cell Metab. 2010;12:213–23. This is a mechanistic studies using a SORT−/− mouse that suggest that Sort1 deficiency is associated with reduced plasma cholesterol and reduced VLDL secretion.

29.

• Ai D, Baez JM, Jiang H, Conlon D, Hernandez-Ono A, Frank-Kamenetsky M, Milstein S, et al. Activation of ER stress and mTORC1 supresses hepatic sortilin-1 levels in obese mice. J Clin Investi. 2012; Apr 2 [Epub ahead of print]. This is a study showing that Sort1 expression is regulated by ER stress and mTOR signaling and demonstrating that elevated Sort1 expression is associated with reductions in VLDL/apoB secretion whereas reduced Sort1 expression is associated with increased VLDL/apoB secretion.

30.

Jansen P, et al. Roles for the pro-neurotrophin receptor sortilin in neuronal development, aging and brain injury. Nat Neurosci. 2007;10:1449–57.PubMedCrossRef

Titel: Sortilin as a Regulator of Lipoprotein Metabolism
verfasst von: Alanna Strong
Daniel J. Rader
Publikationsdatum: 01.06.2012
Verlag: Current Science Inc.
Erschienen in: Current Atherosclerosis Reports / Ausgabe 3/2012
Print ISSN: 1523-3804
Elektronische ISSN: 1534-6242
DOI: https://doi.org/10.1007/s11883-012-0248-x

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren.

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Proximale Humerusfraktur: Auch 100-Jährige operieren?

01.05.2024 DCK 2024 Kongressbericht

Mit dem demographischen Wandel versorgt auch die Chirurgie immer mehr betagte Menschen. Von Entwicklungen wie Fast-Track können auch ältere Menschen profitieren und bei proximaler Humerusfraktur können selbst manche 100-Jährige noch sicher operiert werden.

Die „Zehn Gebote“ des Endokarditis-Managements

30.04.2024 Endokarditis Leitlinie kompakt

Worauf kommt es beim Management von Personen mit infektiöser Endokarditis an? Eine Kardiologin und ein Kardiologe fassen die zehn wichtigsten Punkte der neuen ESC-Leitlinie zusammen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2012

Myeloperoxidase Production by Macrophage and Risk of Atherosclerosis

MicroRNAs as Biomarkers for Myocardial Infarction

Atherosclerosis, Inflammation, Genetics, and Stem Cells: 2012 Update

Liver X Receptors, Atherosclerosis and Inflammation

Targeting Cytokine Signaling as an Innovative Therapeutic Approach for the Prevention of Atherosclerotic Plaque Development